Medplus Health Services Releases Q2 FY'26 Earnings Call Transcript, Highlights Revenue and Store Growth
Medplus released its Q2 FY'26 earnings call transcript, reporting ₹1,679.30 crore revenue and ₹88.70 crore EBITDA. The company expanded its store network, grew diagnostics, and expects SSSG to reach high-single digits.
The impact is high as this announcement provides a comprehensive update on the company's financial performance, operational achievements (store expansion, diagnostics growth), and strategic outlook for future growth and profitability, which are crucial for investor decision-making.
The sentiment is positive due to strong Q2 FY'26 financial performance, significant store expansion, improved diagnostics segment profitability, and management's optimistic outlook for future Same-Store Sales Growth and continued store additions. The employee retention plan also shows positive effects on attrition.
Medplus Health Services Limited has submitted the transcript of its Earnings Call held on November 03, 2025, for the quarter and half year ended September 30, 2025. Key highlights from the call include: * Consolidated revenue for Q2 FY'26 stood at ₹1,679.30 crore (INR16,793 million). * Consolidated operating EBITDA for the quarter was ₹88.70 crore (INR887 million), representing a 5.3% margin. * Revenue from pharmacy operations grew by 8.8% year-on-year on a GMV basis and 6.3% year-on-year on a net basis, with an operating EBITDA of ₹83.90 crore (INR839 million), representing a 5.1% margin. * The company opened 145 new stores during the quarter, achieving a net addition of 117 stores. The total network expanded to 4,930 stores covering 2.6 million+ square feet. * Medplus maintains its outlook of adding 600 new stores in fiscal '26. * Private label sales constituted 21.5% of total revenues in Q2 FY'26, with pharma at 12.1% and non-pharma at 9.6%. * The diagnostics segment's revenue grew to ₹33.25 crore (INR332.5 million) in Q2 FY'26 compared to ₹28.31 crore (INR283.1 million) in Q2 FY'25. * Diagnostics segment operating EBITDA improved significantly to ₹5.09 crore (INR50.9 million), representing 15.3%, compared to ₹2.10 crore (INR21 million) in Q2 FY'25. * As of September 30, 2025, there were 170,000 active diagnostic plans covering 351,000 lives. * The company implemented an employee retention plan, offering a ₹18,000 one-time cash bonus after 12 months, increasing to ₹50,000 and ₹1 lakh for subsequent rollovers, which has led to a significant reduction in attrition in key cities. * Pre-operative costs were around ₹3.4 crore in Q2, primarily due to property bank and initial employee training. * Management expects Same-Store Sales Growth (SSSG) to gradually increase and reach high-single digits (9-10%) in the next two years. Annual store additions of 600 to 1,000 are planned, with potential for higher if the franchisee model takes off.
What to do with a filing like this
Medplus Health Services Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Medplus Health Services Limited. Read the original for the full detail.